参考文献/References:
[1]Chuang YC,Liu SP,Lee KS,et al.Prevalence of overactive bladder in China, Taiwan and South Korea:results from across-sectional,population-based study[J].Low Urin Tract Symptoms,2019,11(1):48-55. [2]Milsom I,Coyne KS,Nicholson S,et al.Global prevalence and economic burden of urgency urinary incontinence:a systematic review[J].Eur Urol,2014,65(1):79-95.[3]Symonds T.A review of condition-specific in struments to assess the impact of urinary incontinence on health-related quality of life[J].Eur Urol,2003,43(3):219-225.[4]Sanford M.Mirabegron:a review of its use in patients with overactive bladder syndrome[J].Drugs,2013,73(11):1213-1225.[5]Andersson KE.Prospective pharmacologic therapies for the overactive bladder[J].Ther Adv Urol,2009,1(2):71-83.[6]Moher D,Shamseer L,Clarke M,et al.Preferred reporting items for systematic review and meta-analysis protocols(PRISMA-P)2015 statement[J].Syst Rev,2015,4(1):1. [7]Abrams P,Kelleher C,Staskin D,et al.Combination treatment with mirabegron and solifenacin in patients with overactive bladder:efficacy and safety results from a randomised,double blind,dose-ranging,phase 2 study(Symphony)[J].Eur Urol,2015,67(3):577-588.[8]Batista JE,Kolbl H,Herschorn S,et al.The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy:results of a noninferiority,randomized, phase Ⅲb trial[J].Ther Adv Urol,2015,7(4):167-179.[9]Herschorn S,Chapple CR,Abrams P,et al.Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder(SYNERGY study)[J].BJU Int,2017,120(4):562-575.[10]Gratzke C,van Maanen R,Chapple C,et al.Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder:a randomised, multicentre phase 3 study(SYNERGY Ⅱ)[J].Eur Urol,2018,74(4):501-509.[11]Nitti VW,Auerbach S,Martin N,et al.Results of a randomized phase Ⅲ trial of mirabegron in patients with overactive bladder[J].J Urol,2013,189(4):1388-1395.[12]Khullar V,Amarenco G,Angulo JC,et al.Efficacy and tolerability of mirabegron,a beta(3)-adrenoceptor agonist,in patients with overactive bladder:results from a randomised European-Australian phase 3 trial[J].Eur Urol,2013,63(2):283-295.[13]Herschorn S,Barkin J,Castro-Diaz D,et al.A phase Ⅲ,randomized,double-blind,parallelgroup, placebo-controlled,multicentre study to assess the efficacy and safety of the β3 adrenoceptor agonist,mirabegron, in patients with symptoms of overactive bladder[J].Urology,2013,82(2):313-320.[14]Yamaguchi O,Marui E,Kakizaki H,et al.Phase Ⅲ,randomised,doubleblind,placebo-controlled study of the beta3-adrenoceptor agonist mirabegron,50 mg once daily, in Japanese patients with overactive bladder[J].BJU Int,2014,113(6):951-960.[15]Kuo HC,Lee KS,Na Y,et al.Results of a randomized,double-blind, parallel-group,placebo-and active-controlled,multicenter study of mirabegron,a beta3-adrenoceptor agonist,in patients with overactive bladder in Asia[J].Neurourol Urodyn,2015,34(7):685-692.[16]Rosa GM,Ferrero S,Nitti VW,et al.Cardiovascular Safety of 3-adrenoceptor Agonists for theTreatment of Patients with Overactive Bladder Syndrome[J].European Urology,2016,69(2):311-323.[17]王梓阳,姜成龙,廖鹏腾,等.米拉贝隆与托特罗定治疗膀胱过度活动症的Meta分析[J].现代泌尿外科杂志,2019,24(2):122-127[18]Sebastianelli A,Russo GI,Kaplan SA,et al.Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder:Comparison with placebo and tolterodine[J].Int J Urol,2018,25(3):196-205.[19]Xu Y,Liu R,Liu C,et al.Meta-Analysis of the Efficacy and Safety of Mirabegron Add-On Therapy to Solifenacin for Overactive Bladder[J].International Neurourology Journal,2017,21(3):212-219.